Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

Teva's biosimilars business is expected to roughly double to about $800 million by 2027, with two products already on the U.S. market and three more under FDA review. However, the article argues the stock's main comeback is being driven by branded drugs like Austedo, which reached about $2.3 billion in 2025 sales, while 2026 revenue is expected to be flat to lower. At around 25x trailing P/E, the stock is described as fairly valued rather than a bargain.

Analysis

The market is paying for a turnaround multiple while the incremental growth engine is still a low-quality mix shift toward biosimilars. That matters because biosimilars typically add revenue before they add durable earnings power: pricing pressure, partner economics, and launch sequencing mean the top line can grow faster than gross profit. In other words, the next leg up in TEVA likely requires operating leverage from the branded portfolio, not just more biosimilar launches.

The second-order effect is on the competitive set. If PBMs continue to push deeper substitution, the biosimilar winner is less likely to be the manufacturer and more likely to be the payer/intermediary that controls access and rebate capture; that compresses the long-run margin pool for ALVOW and TEVA while strengthening larger branded incumbents with entrenched contracting power. ABBV is the clearest example of a company that can absorb biosimilar erosion in one franchise while still monetizing another, which is why the market is punishing the biosimilar narrative more than the total-addressable-market narrative.

The key risk is timing: the thesis can look good for quarters before it looks good in P&L. A six-to-twelve-month window is where launch share gains could keep sentiment supported, but over a 2-3 year horizon the economics likely normalize toward a thin-margin specialty/generic profile unless the branded pipeline keeps compounding. The contrarian read is that the stock may not be expensive on an absolute basis, but it is expensive relative to the quality of the growth engine and the probability of additional multiple expansion.

What the market may be missing is that TEVA’s upside is now more sensitive to execution in branded launches and less sensitive to biosimilar volume. If Austedo growth slows even modestly, the valuation support weakens quickly because the biosimilar segment is not high enough margin to backfill the miss. That creates an asymmetric setup where good news on launches moves the stock less than bad news on branded deceleration.

Key Decisions for Investors

• Avoid initiating new longs in TEVA here; if already long, consider trimming into strength and using a 3-6 month horizon, because the current multiple leaves limited room for rerating unless branded growth reaccelerates.
• Pair trade: long ABBV / short TEVA for 6-12 months. Thesis: ABBV has better pricing power and earnings durability, while TEVA’s biosimilar mix is more exposed to rebate pressure and margin dilution. Target a relative outperformance spread of 10-15%.
• Speculative trade: buy small size ALVOW weakness on pullbacks only, with a 6-9 month horizon. Upside comes from optionality on Teva-partnered launches, but position size should be capped because economics are partner-shared and competition erodes launch pricing quickly.
• For event-driven accounts, sell TEVA downside via put spreads rather than shorting stock outright. A 3-4 month put spread captures the risk of branded deceleration while defining risk if the market keeps rewarding the turnaround narrative.
• Set a catalyst watch on TEVA earnings over the next 1-2 quarters: if biosimilar revenue beats but operating margin does not expand, fade the move. That would confirm the market is overestimating the earnings contribution of the biosimilar ramp.